Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Emphasis on accessible, low-toxicity treatments, including oral therapies, to reduce financial burden and improve patient ...

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Treatment with Zervyteg (MaaT013) generated encouraging results and demonstrated an acceptable safety profile in patients with acute graft-vs-host disease that affects the gastrointestinal tract and ...

Orlowski serves as chairman, Ad Interim, and director of Myeloma in the Departments of Lymphoma/Myeloma and Experimental ...

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

Accurate information about Lynch syndrome is essential. As more people discuss hereditary cancer online, misinformation ...

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...